http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 MISSISSAUGA, ON, Nov. 11 - CML HealthCare Income Fund (the "Fund" or "CML HealthCare"), (TSX: CLC.UN) today reported its financial results for the three and nine-month periods ended September 30,... http://pharmalicensing.com/redirs/news_rss//public/news/view/499745/0/6/cml-healthcare-income-fund-reports-2009-third-quarter-financial-results http://pharmalicensing.com/redirs/news_rss//public/news/view/499745/0/6/cml-healthcare-income-fund-reports-2009-third-quarter-financial-results Basel, Switzerland, 10 November 2009 - Lonza announces that GlaxoSmithKline (GSK) and Genmab's antibody ArzerraTM, which has just been approved for use in patients with chronic lymphocytic leukemia... http://pharmalicensing.com/redirs/news_rss//public/news/view/499602/0/6/lonza-successfully-develops-a-manufacturing-process-for-arzerratm-ofatumumab-a-new-biopharmaceutical-from-gsk-and-genmab http://pharmalicensing.com/redirs/news_rss//public/news/view/499602/0/6/lonza-successfully-develops-a-manufacturing-process-for-arzerratm-ofatumumab-a-new-biopharmaceutical-from-gsk-and-genmab CAMBRIDGE, Mass. November 4, 2009 Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone,... http://pharmalicensing.com/redirs/news_rss//public/news/view/498877/0/6/acceleron-pharma-initiates-first-in-human-study-of-ace-041-a-novel-angiogenesis-inhibitor-in-patients-with-advanced-cancer http://pharmalicensing.com/redirs/news_rss//public/news/view/498877/0/6/acceleron-pharma-initiates-first-in-human-study-of-ace-041-a-novel-angiogenesis-inhibitor-in-patients-with-advanced-cancer MISSISSAUGA, ON, Nov. 4 - CML HealthCare Income Fund (TSX: CLC.UN), will release its 2009 third quarter financial results via www.newswire.ca prior to markets opening on November 11th , 2009.... http://pharmalicensing.com/redirs/news_rss//public/news/view/498810/0/6/cml-healthcare-income-fund-announces-release-date-for-fiscal-2009-third-quarter-financial-results http://pharmalicensing.com/redirs/news_rss//public/news/view/498810/0/6/cml-healthcare-income-fund-announces-release-date-for-fiscal-2009-third-quarter-financial-results RARITAN, N.J. (Oct. 23, 2009) - Ortho Clinical Diagnostics announced the launch of FETALSCREEN(TM) II Fetal Maternal Hemorrhage Screening Test, a simple, qualitative test that detects D (Rho)... http://pharmalicensing.com/redirs/news_rss//public/news/view/499817/0/6/ortho-clinical-diagnostics-launches-fetalscreen-tm-ii-fetal-maternal-hemorrhage-screening-test http://pharmalicensing.com/redirs/news_rss//public/news/view/499817/0/6/ortho-clinical-diagnostics-launches-fetalscreen-tm-ii-fetal-maternal-hemorrhage-screening-test MADISON, N.J., June 22, 2009 -- HemoCue Inc., the U.S. point-of-care testing distribution subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced that it has signed an agreement... http://pharmalicensing.com/redirs/news_rss//public/news/view/496950/0/6/diagnostics-hemocue-subsidiary-to-add-u-s-hospital-laboratory-connectivity-to-its-hemocue-201-dm-point-of-care-systems http://pharmalicensing.com/redirs/news_rss//public/news/view/496950/0/6/diagnostics-hemocue-subsidiary-to-add-u-s-hospital-laboratory-connectivity-to-its-hemocue-201-dm-point-of-care-systems Brookline, MA, October 7,2008 -- Tarix Phamaceuticals today announced that the University of Southern California has received a grant to study the effects of TXA127 in preventing thrombocytopenia... http://pharmalicensing.com/redirs/news_rss//public/news/view/496744/0/6/university-of-southern-california-receives-1-million-nih-grant-to-study-txa127-for-the-prevention-of-radiation-damage http://pharmalicensing.com/redirs/news_rss//public/news/view/496744/0/6/university-of-southern-california-receives-1-million-nih-grant-to-study-txa127-for-the-prevention-of-radiation-damage Brookline,MA , June 25, 2008 -- Tarix Phamaceuticals announced that it has received FDA approval to begin a Phase II clinical trial of TXA127 for the prevention of chemotherapy induced... http://pharmalicensing.com/redirs/news_rss//public/news/view/496745/0/6/tarix-pharmaceuticals-receives-fda-approval-for-phase-2-study-to-mitigate-chemotherapy-induced-thrombocytopenia http://pharmalicensing.com/redirs/news_rss//public/news/view/496745/0/6/tarix-pharmaceuticals-receives-fda-approval-for-phase-2-study-to-mitigate-chemotherapy-induced-thrombocytopenia